Cladribine Injection 10 mg/10 mL is a sterile aqueous solution of cladribine, C₁₀H₁₂ClN₅O₃, at a labelled strength of 10 mg per 10 mL and a nominal concentration of 1 mg/mL. The active substance is identified by CAS 4291-63-8 and has a relative molecular mass of 285.69 g/mol. The container is a single-dose Type I borosilicate glass vial with a chlorobutyl elastomeric closure, controlled under USP <660> and USP <381>. The label designation “Pharma Grade API for Tablet / Capsule / Granule / Injection, Oral & Injectable” defines this item as a pharmaceutical-grade active pharmaceutical ingredient source for downstream manufacture; it is not a technical-grade chemical. The vehicle consists of Water for Injection and sodium chloride, with pH adjustment to the validated range using hydrochloric acid or sodium hydroxide. The vial is intended for a single entry in an ISO 5 or better compounding environment unless the entry is part of a closed-system transfer process. For manufacture of solid oral dosage forms, the solution is transferred volumetrically or gravimetrically; the dilution factor must be traced on the batch record, and the rinse volume is validated to achieve target cladribine recovery.

Cladribine is a chlorinated purine nucleoside analogue. Intracellular phosphorylation by deoxycytidine kinase yields 2-chloro-2′-deoxyadenosine 5′-triphosphate, which inhibits DNA polymerase and ribonucleotide reductase in lymphoid cells. This mechanism underlies the use of cladribine in hairy-cell leukaemia and relapsing multiple sclerosis. The liquid API is not a final infusion product; it is a manufacturing input. Its concentration of 1 mg/mL provides the basis for volumetric batch calculations, but the final label claim of any tablet, capsule, granule, oral liquid, or injectable product must be established independently through the finished-product specification.

Which compendial release controls apply to a liquid cladribine API presentation?

The lot release matrix combines assay and related-substance chromatography with parenteral safety tests. Assay and related substances are measured by reversed-phase high-performance liquid chromatography with ultraviolet detection at 265 nm. System suitability includes separation of cladribine from 2-chloroadenine at a resolution of not less than 1.5. Because the maximum parenteral daily dose is below 2 g/day, reporting, identification, and qualification thresholds for unspecified impurities follow the ICH Q3A cut-offs of 0.05%, 0.10%, and 0.15%, respectively. Residual solvents are not added to the formulation; any solvent carried from cladribine synthesis is controlled by headspace gas chromatography under ICH Q3C. Elemental impurities are controlled by an ICH Q3D risk assessment, with routine testing or supplier confirmation for arsenic, cadmium, mercury, and lead as appropriate. The sterile injectable presentation is released only after membrane filtration testing demonstrates no growth in fluid thioglycollate medium at 30–35 °C for 14 days and soybean casein digest medium at 20–25 °C for 14 days. Particulate matter is limited by the light obscuration method of USP <788>; for a container below 100 mL, the acceptance criterion is not more than 6000 particles per container at ≥10 µm and not more than 600 particles per container at ≥25 µm. Bacterial endotoxins are measured by Limulus amebocyte lysate kinetic chromogenic or gel-clot techniques, with a limit calculated from the labelled dose and route.

The specification is generated under ICH Q6A decision-tree logic. If a parameter is demonstrated to be controlled by the manufacturing process and supplier quality system, it may be assigned skip-lot testing; however, identification, assay, pH, sterility, bacterial endotoxins, particulate matter, and visible particles remain routine for the injectable API. The manufacturer’s drug master file includes a stability-indicating HPLC method validated for specificity, forced degradation, linearity, accuracy, precision, and solution stability. The liquid formulation employs no organic solvent in the final vehicle; any synthesis-related solvent is confirmed below the appropriate ICH Q3C concentration limit using headspace gas chromatography.

On automated filling lines, low-concentration injectable solutions require fill-weight feedback and periodic checkweighing. The principal production failure mode is not chemical degradation but subvisible particle formation in the fluid path. Silicone tubing segments, peristaltic pump compression, and fill-needle friction can introduce particle excursions; therefore, the batch record includes in-process particulate monitoring and requires replacement intervals for product-contact elastomers. Published data for this specific configuration is limited, so filter compatibility and hold time must be qualified for each line configuration before commercial filling.

Cladribine Injection 10 mg/10 mL is not interchangeable with technical-grade, lyophilized, or oral tablet feedstocks

The liquid presentation eliminates the reconstitution step required for lyophilized powder. Lyophilized product is controlled for residual moisture by USP <921>; the liquid presentation is controlled for assay loss and particle formation under defined storage. The two forms are not equivalent in downstream handling: a lyophilized cake must be reconstituted with a controlled diluent, whereas a liquid API can be transferred directly into a sterile mixing vessel. Oral tablet and capsule intermediates, by contrast, are handled as dry powders or granules and are tested under USP <711> dissolution and USP <905> content uniformity after compression or encapsulation. A technical-grade cladribine powder is non-sterile, may exhibit an uncontrolled impurity profile, and is not released under ICH Q7; substitution into pharmaceutical manufacture is unacceptable.

Cladribine differs from fludarabine phosphate and pentostatin by the 2-chloro substitution on the adenine ring. The structural feature reduces deamination by adenosine deaminase, allowing intracellular accumulation of cladribine triphosphate in lymphoid cells. Fludarabine phosphate requires initial dephosphorylation to 2-fluoro-ara-A before intracellular activation; pentostatin inhibits adenosine deaminase directly. These differences produce distinct dosing schedules, reconstitution or dilution requirements, and toxicity profiles. A conversion between cladribine and fludarabine or pentostatin by simple molecular-weight or molarity correction without reference to the labelled product concentration is not valid in compounding or manufacturing. Published pharmacokinetic data report oral bioavailability of approximately 40% relative to intravenous administration; therefore, oral tablet dose strength and injectable concentration cannot be interchanged directly without pharmaceutical or clinical assessment.

Sterile processing, container closure integrity, and downstream formulation handling

Cladribine in aqueous solution is sensitive to alkaline pH and oxidative conditions. Manufacturing vessels use a nitrogen overlay to reduce dissolved oxygen; the pH is maintained in the validated range, and the solution is filtered through a sterilising-grade 0.22 µm membrane under aseptic conditions. Terminal sterilization is not assumed for this liquid presentation; if a site proposes autoclaving, the thermal cycle must be justified against degradation data. Container closure integrity is verified by vacuum decay or dye ingress under USP <1207>. Fill volume is released under USP <697>, and the sterility assurance level of the validated aseptic process is monitored through media fills and environmental monitoring.

For tablet or capsule manufacture, the aqueous solution is used as a granulating fluid. A high-shear granulator or fluid-bed granulator with dew-point-controlled inlet air receives the solution; the aqueous vehicle increases drying load compared with ethanolic granulation and requires loss-on-drying control under USP <731>. The dried granulation is milled and blended, then compressed or encapsulated. The final oral solid dosage form is tested for blend uniformity, content uniformity, dissolution, and residual moisture. Because cladribine is incompatible with strong oxidising agents, the granulation matrix should avoid peroxide-containing excipients. For injectable manufacture, the solution is diluted into a compatible infusion vehicle, typically 0.9% sodium chloride injection or 5% dextrose injection, followed by final sterilising-grade filtration and aseptic filling into the final container. Hold times between dilution and filling must be validated for chemical stability and bioburden control.

The concentration of 1 mg/mL in the source vial is not the final infusion concentration for clinical use. It is a manufacturing concentration that permits quantitative transfer and dilution. For parenteral dosage, the final product must meet the labelled concentration, osmolality, pH, and volume in the container; for oral liquid preparation from the API, preservative efficacy must be evaluated if a multi-dose container is used. For granulation, the concentration must be accounted for in the binder solution calculation; loss on drying does not remove cladribine, so the assay of the dried granulation remains proportionate to the input. Strong oxidising agents, alkaline processing fluids, and incompatible cationic polymers that may precipitate cladribine should be excluded from the manufacturing stream.